Osteopore™

INVESTOR PRESENTATION

MAY 2021

DISCLAIMER

This presentation has been prepared by Osteopore Limited and its related entities (the "Company"). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US Disclosure

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). The Company's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

TRANSFORMATIVE BONE REGENERATION PRODUCTS

BREAKTHROUGH TECHNOLOGY

Unique implants that facilitate vascularisation to accelerate bone and tissue regeneration

PROPRIETARY 3D PRINTING TECHNOLOGY

All Osteopore products are fabricated in-house using low cost, proprietary 3D printing technology

IMPROVES LIVES

Extremely low probability of issues after surgery compared to bone grafts and permanent implants

REVENUE INCREASING

Revenue is growing as surgeons increasingly switch from traditional products to Osteopore implants

TARGETING THE SIGNIFICANTLY UNTAPPED US$3.9BN BONE GRAFT & US$100BN PERMANENT IMPLANT MARKET WITH <u>SUPERIOR PRODUCTS</u>

Source for market size data: Allied Market Research, BCC Research

INVESTMENT HIGHLIGHTS

REGULATORY CLEARANCE

Osteopore's products are cleared by the US FDA, Australian TGA and some bear the CE mark of conformity

SCALABLE BUSINESS MODEL

High margin products with low manufacturing capital intensity provide significant opportunity to scale the business and enter new markets

LOW RISK PROFILE

With significant investment already undertaken in product development and clinical trials, Osteopore is directing capital towards commercial activities

GROWING REVENUE

AUD$1.5 million in revenue for the twelve-month period to 31 December 2020, with around 50,000 successful treatments to date

HIGHLY CREDENTIALED TEAM

The Company has a highly credentialed, collaborative and experienced team to progress the commercialisation and expansion of the Company's technology

GROWING REVENUE & MARGINS

QUARTERLY SALES REVENUE IN SGD (THOUSAND)



Record Q1 CY21 revenue of S$327,622

21% increase in over the previous year sales for the corresponding period

A gross margin of 68.2% of sales revenue was achieved in Q1 CY21

Osteopore’s cost effective and high margin manufacturing process will become a major contributor towards achieving profitability

ROBUST CASH POSITION TO DRIVE GROWTH

Shares on Issue [A]	**117.2m**
Total Options on Issue [B]	13.1m
Market Cap @ $0.475c [C]	**$55.6m**
EV @ $0.475 [C]	$47.7m
CASH BALANCE [D]	**$7.9m**
FY20 Average Quarterly Net Operating Cash Used	($388k)

A: Shares on Issue includes 16.0m placement shares.

B: 9.7m options with an exercise price of $0.25 and an expiry date of 30 June 2022, 0.4m options with an exercise price of $1.00 and an expiry date in December 2022, 3m options with exercise price of $1.20 and expiry August 2023. Option incentives held by executive management, directors & advisors.

C: Market Close, 27 May 2021

D: Cash balance at 31 March 2021





COMMERCIAL STRATEGY THAT BUILDS VALUE

#1 ACCELERATE REVENUE GROWTH

Revenue growth from our current product range is the highest corporate and commercial priority and will remain the focus throughout the lifecycle of the company

Osteoplug™

Osteomesh™

Osteostrip

#2 DIVERSIFY PRODUCT RANGE

Osteopore is undertaking Several development programs to launch new products and expand the scope of bone regeneration applications

#3 INNOVATE

Undertaking a number of early-stage, low-capital intensity development projects with large potential upside

COMPANY VALUE

TIME FRAME

SCALABLE OPPORTUNITY

- Osteopore has superior off-the-shelf products that can be manufactured at scale and is used in over 1.1m procedures globally
- Long shelf-life products that can be stocked in a hospitals inventory system

Osteostrip

Osteoplug™

SURGERY TYPE	TOTAL NUMBER OF SURGERIES IN 2020 [7]
Craniotomy / Craniotomy closure	359,428
Burr hole for hematoma evacuation	302,570
Craniectomy	89,134
Burr hole for shunt placement	74,203
Endoscopic third ventriculostomy	65,730
Cranioplasty	51,247
Skull base repair	48,958
Burr hole for drain placement	46,413
Burr hole for biopsy	33,520
Cranial reconstruction	19,897
Craniosynostosis repair	11,588
USG guided external ventricular drain insertion	3,845
Burr hole for exploration	3,229
TOTAL	1,109,764

Sources located in in Appendix slide

BREAKTHROUGH BIORESORBABLE PRODUCTS FOR MULTIPLE APPLICATIONS

Osteoplug™

Implant that is used for covering Burr Holes (holes in skull) after neurosurgery

REGULATORY APPROVAL

SALES GENERATING

Osteomesh™

Implant used in craniofacial surgery to repair bone in the skull, neck and jaw, including repairing orbital floor fractures

REGULATORY APPROVAL

SALES GENERATING

OSTEOPORE PSI

Custom-designed patient specific implants used throughout the body

SALES GENERATING

1.1 MILLION PROCEDURES PA

Osteostrip

Implant that is used to fill the void following a craniotomy (the surgical removal of part of the bone from the skull to expose the brain)

REGULATORY APPROVAL

SALES GENERATING

DENTAL

Dental plug which promotes vertical bone growth in the jaw following tooth removal

US$1BN PA*

DENTAL BONE GRAFT ALTERNATIVES MARKET

REGULATORY APPROVAL †

SALES GENERATING

ORTHOPAEDIC

A scaffold used in a range of orthopaedic procedures, where significant lengths of long bones have been damaged

US$2BN PA*

SALES OF ORTHOPAEDIC ALTERNATIVES

INVESTIGATIVE DEVICE

SPECIAL ACCESS SALES

* Source for market size data: Allied Market Research, BCC Research

† Regulatory approval in Singapore

IMPROVED PATIENT OUTCOMES & LOWER HEALTHCARE COSTS

- Osteopore products address an unmet clinical need by providing readily adaptable implants and reducing complication rates after surgery
- Provides hospitals, clinicians and patients with a proven solution that expedites recovery and lowers costs that may occur with traditional procedures in the event of complications

Bone Graft — **6 – 19%** [1,2,3]

REPORTED COMPLICATION RATES

Permanent Implants — **25 – 33%** [4,5,6]

REPORTED COMPLICATION RATES

Osteopore™ — **0.01%**

Sources listed on slide 16

23 | DISTRIBUTION PARTNERS

13 | PARTNERS SECURED IN 2020

EXPANDING DISTRIBUTION NETWORK

CURRENTLY TARGETING **~1.1 million**[7] CRANIAL PROCEDURES GLOBALLY



REVENUE GROWTH STRATEGY

Leverage distribution partnerships in the key markets to accelerate revenue growth

Ensure sales teams and surgeons are educated and supported to drive adoption and sales

Leverage early adopters in sales and marketing campaigns to achieve product sales momentum

Increase underlying revenue through a mix of geographic expansion and adjacent clinical applications

* In brackets, the number of cranial procedures undertaken in 2020.

FOUNDATIONAL MARKETS

ASIA

- Well established and experienced distribution partner network in South Korea, Vietnam, Singapore and Australia
- 2020 constant currency year-on-year revenue growth of 39%
- Expanded range of clinical applications, including aesthetic surgery
- Emerging dental application sales in Singapore
- Orthopaedic application clinical trials underway in Singapore, Vietnam and Malaysia

AUSTRALIA & NZ

- Hired dedicated Business Development person in Sydney Australia
- Signed Australian & NZ distribution agreement with LMT Surgical
- Education and training for LMT sales team
- Achieve initial sales
- Support clinical trial for dental application

PRIORITY MARKET EXPANSION

Recently received CE Mark for expanded product variants and shelf life





Europe + UK

- Signed German-Austrian Distribution Agreement with MTG Medizintechnik Göhl GmbH
- Initial stocking order for Osteopore products from MTG Medizintechnik Göhl GmbH
- Identify & engage with Key Opinion Leaders surgeons across broader Europe + UK
- Achieve initial stocking orders

USA

- Signed US Distribution Agreement with Bioplate
- First “stocking” order with Bioplate
- Education and training for Bioplate sales team
- Secure additional U.S. distribution partnerships to cover more states
- Initiate 510k regulatory approval for dental and orthopedic products

CHINA

- Signed Co-operation agreement with Boao Yiling Life Care Centre in China
- Establish a subsidiary in the Suzhou Industrial Park as the first step towards obtaining Chinese regulatory approval
- Prepare NMPA dossier for regulatory approval

JAPAN

- Identify and engage KOL surgeons interested in adopting Osteopore products
- Identify potential distribution partners with strong ties to hospitals specialising in craniofacial procedures
- Develop the necessary education and training materials
- Achieve initial stocking order

FUTURE COMMERCIAL OPPORTUNITIES

Osteopore is conducting several early-stage research initiatives with high quality institutions that could present significant commercial opportunities.



REGENERATION OF OTHER TISSUE

Osteopore has successfully completed animal trials for knee cartilage regeneration, and the Osteopore scaffold may also potentially be used to assist with the regeneration of other tissue types



VETERINARY MARKETS

Osteopore has successfully completed multiple animal trials for a number of different surgical applications which could possibly translate into products for the veterinarian market



ACCELERATING BONE REGENERATION

Osteopore is investigating the viability of incorporating compounds to produce novel polycaprolactone polymer composites which could be used development additional products for adjacent therapeutic and surgical areas

2021 COMMERCIAL PRIORITIES



ACCELERATE REVENUE GROWTH

Leverage cranial and maxillofacial products with regulatory approval in significant Markets:

- Asia
- USA
- Germany
- Australia & NZ
- Scandinavia

Establish a presence in new markets with a high volume of relevant procedures:

- China
- UK
- Japan

DIVERSIFICATION

Leverage dental product regulatory approval in Singapore to drive sales in Asia

Initiate a dental clinical trial in Australia as the basis for TGA product approval

Initiate FDA approval for dental and orthopaedic products for sale in the USA

Initiate regulatory approval for rhinoplasty in Korea

INNOVATION

Experiment with promising novel compound combinations, including PCL-TCP and PCL-TCP-Mg, facilitating bone and cell growth to improve healing time and patient outcomes

Engage with Terumo BCT to explore the opportunities to combine Osteopore’s resorbable biomimetic scaffolds with Terumo’s autologous biologics

Continuously improve manufacturing efficiency using proven technological improvements in 3D printing to cost effectively scale production

SOURCES

1 Dimitriou, R., Mataliotakis, G. I., Angoules, A. G., Kanakaris, N. K., & Giannoudis, P. V. (2011). Complications following autologous bone graft harvesting from the iliac crest and using the RIA: a systematic review. *Injury*, 42, S3-S15.

2 Younger, E. M., & Chapman, M. W. (1989). Morbidity at bone graft donor sites. *Journal of orthopaedic trauma*, 3(3), 192-195.

3 Arrington, E. D., Smith, W. J., Chambers, H. G., Bucknell, A. L., & Davino, N. A. (1996). Complications of iliac crest bone graft harvesting. *Clinical Orthopaedics and Related Research®*, 329, 300-309

4 Giese, H., Meyer, J., Unterberg, A., & Beynon, C. (2020). Long-term complications and implant survival rates after cranioplastic surgery: a single-center study of 392 patients. *Neurosurgical Review*, 1-9.

5 Wiggins, A., Austerberry, R., Morrison, D., Ho, K. M., & Honeybul, S. (2013). Cranioplasty with custom-made titanium plates—14 years experience. *Neurosurgery*, 72(2), 248-256.

6 Thien, A., King, N. K., Ang, B. T., Wang, E., & Ng, I. (2015). Comparison of polyetheretherketone and titanium cranioplasty after decompressive craniectomy. *World neurosurgery*, 83(2), 176-180.

7 cetas healthcare (2020). Market research conducted for Osteopore on the global cranial procedure market.

8 Sparks, D. S., Saifzadeh, S., Savi, F. M., Dlaska, C. E., Berner, A., Henkel, J., ... & Hutmacher, D. W. (2020). A preclinical large-animal model for the assessment of critical-size load-bearing bone defect reconstruction. *Nature protocols*, 15(3), 877-924.

9 Zhang, Z., & Teoh, S. H. (2014). Novel 3D polycaprolactone scaffold for ridge preservation – a pilot randomised controlled clinical trial. *Clinical Oral Implants Research*, 26, 271-277.

10 van Griensven, M., Biberthaler, P., & Rosado Balmayor, E. (2015). Clinical approaches to the healing of long bone defects. In Schantz, J-T. & Hutmacher, D.W. (2020), *Advanced Therapies in Regenerative Medicine*, Vol. 2, World Scientific, (pp. 217-231).

Osteopore™

Carl Runde

Chief Financial Officer

M +61 400 118 017

E: carl_runde@osteopore.com